Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided venetoclax bridging to convert continuous BTK inhibitor therapy to time-limited therapy in CLL
ChiCTR2600122699Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, ibrutinib, zanubrutinib and obinutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by West China Hospital of Sichuan University. Primary endpoints: Optimal MRD rate and Safety. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
venetoclaxibrutinibzanubrutinibobinutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ChiCTR2600122699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122699.